康泰生物：终止与阿斯利康设立合资公司

Core Viewpoint - The company announced the termination of the investment agreement with AstraZeneca due to significant market changes and high risks in the vaccine industry [1] Group 1: Investment Agreement - The company planned to establish a joint venture with AstraZeneca focusing on vaccines, with a registered capital of 345 million RMB (approximately 50 million USD) [1] - Both the company and AstraZeneca were to hold 50% equity in the joint venture, with a total investment estimated at around 400 million USD (approximately 2.76 billion RMB) [1] - The decision to terminate the investment was made after careful evaluation and discussions among the parties involved, acknowledging the high risks associated with new investments in the vaccine sector [1] Group 2: Board Decisions - The termination of the investment agreement was approved during the company's eighth board meeting held on February 6, 2026 [1] - The board authorized the management to finalize and sign the relevant termination agreements with the partners [1]